MissionIR Articles
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, raised approximately $1.6 million from its latest round of investment in what will mark a significant milestone for the company. In September 2023, the…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Inks Global Collaboration, License Agreement with SulfoSyn
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive global use of all nonpharmaceutical applications of Lexaria’s…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competition
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Upcoming $1.6M Registered Direct Offering
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a securities purchase agreement with a single healthcare-focused institutional investor; the agreement is for the purchase of 1,618,330 shares of common…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-processed glucagon-like peptide-1 (“GLP-1”) drugs such as, but not limited…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming Investigational New Drug Application Submission
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming Investigational New Drug (“IND”) submission. The application is for the company’s planned US Phase 1b Hypertension Clinical Trial…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming submission of an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial, dubbed…
-
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee
Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people…
-
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth
Lexaria Bioscience (NASDAQ: LEXX), a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform, continues to devote an increasing proportion of its resources and…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Update on IND Application Progress
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today provided an update on the status of its anticipated submission of an Investigational New Drug (“IND”) application with the U.S. Food and…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications.…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss.…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial